Proactive Investors - Run By Investors For Investors

Immupharma PLC recruiting in Europe for Lupus trial

Recruiting patients in Europe has now begun for the pivotal phase III trial of Lupuzor, the firm said.
Immupharma PLC recruiting in Europe for Lupus trial
Overall recuitment is set to take place in up to 45 investigator sites


Recruiting patients in Europe has now begun for the pivotal phase III trial of Lupuzor, aimed at treating the autoimmune disease Lupus, Immupharma PLC (LON:IMM) said today.

It follows news last month that first patients in the USA had begun dosing.

Chairman of the company Tim McCarthy said: "Following the initial US sites being opened and the first Lupus patients having commenced dosing we are delighted that we have hit another key milestone with patient recruitment started in our first European site in France."

The site is in Bordeaux, France and overall recuitment will take place in up to 45 investigator sites with ten in the USA and 35 in Europe to include France, Hungary, Poland, Germany, Czech Republic, Italy and the UK.

 "We look forward to providing further positive updates on this Lupuzor Phase III study as it progresses throughout this year and 2017," added McCarthy.

Systemic Lupus Erythematosus (SLE) is a debilitating and painful disease, which sees the body's immune system turn against itself for reasons still not fully understood.

It is much more common in women, appears most often in African-Americans, Asians and Hispanics and it is estimated that up to five million individuals worldwide may be affected.

The company does not claim Lupuzor is a cure but it hopes it will offer significant relief to sufferers such that their quality of life is greatly improved.

Earlier this month, the group confirmed it had raised a total £8.4mln to advance the potential blockbuster drug Lupuzor

Broker Panmure has placed its recommendation on the stock under review further to the announced recent capital raising and will be updating in due course.

Shares eased 2.43% to 26.10p.

Why Invest In ImmuPharma PLC? Read More Here

Register here to be notified of future IMM Company articles
View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use